Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 14Thoracic 2Dermatologic 2Sarcoma 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 12Carcinoma, Neuroendocrine 5Carcinoid Tumor 3Small Cell Lung Carcinoma 2Gastro-enteropancreatic neuroendocrine tumor 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urethral Neoplasms 1Urachal cancer 1Urachal adenocarcinoma 1Trophoblastic Neoplasms 1Thyroid Neoplasms 1Sertoli-Leydig Cell Tumor 1Secretory breast carcinoma 1Sarcoma, Kaposi 1Sarcoma 1Penile Neoplasms 1Parathyroid Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Mesothelioma 1Lung Neoplasms 1Leiomyosarcoma 1Hepatoblastoma 1Hemangiosarcoma 1Hemangioblastoma 1Granulosa Cell Tumor 1Genital Neoplasms, Female 1

Interventions

cabozantinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Nivolumab × NET × Clear all
NCT05263050 2026-05-22

Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors

Fox Chase Cancer Center

Phase 2 Recruiting
111 enrolled
EndocrineGenitourinaryNET

Clear-cell metastatic renal cell carcinoma, Carcinoid Tumor, Carcinoma, Renal Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡